La Jolla Pharmaceutical

La Jolla inks royalty deal to support Giapreza launch
La Jolla inks royalty deal to support Giapreza launch
Biopharma Dive
La Jolla Pharmaceutical
HealthCare Royalty Partners
Giapreza
drug launches
shock
Flag link:
La Jolla grabs $125M royalty deal to back drug launch, fund R&D
La Jolla grabs $125M royalty deal to back drug launch, fund R&D
Endpoints
La Jolla Pharmaceutical
Giapreza
Flag link:
3 Biotechs Launching Their First Commercial Drugs in 2018
3 Biotechs Launching Their First Commercial Drugs in 2018
Motley Fool
biotech
drug launches
Flexion
Zilretta
osteoarthritis of the knee
La Jolla Pharmaceutical
Giapreza
shock
Portola Pharmaceuticals
Bevyxxa
venous thromboembolism
Flag link:
3 Biotech Stocks Bucking the Stock Market Crash
3 Biotech Stocks Bucking the Stock Market Crash
Motley Fool
biotech
Lexicon Pharmaceuticals
La Jolla Pharmaceutical
Acorda Therapeutics
Flag link:
La Jolla dumps its NASH drug and shifts its focus to rare disease
La Jolla dumps its NASH drug and shifts its focus to rare disease
Fierce Biotech
La Jolla Pharmaceutical
NASH
GCS-100
LJPC-1010
Flag link:
Can La Jolla Phamra Shares Really Double?
Can La Jolla Phamra Shares Really Double?
24/7 Wall St
La Jolla Pharmaceutical
Flag link:
La Jolla Pharma's drug improves kidney function in mid-stage study
La Jolla Pharma's drug improves kidney function in mid-stage study
Yahoo/Reuters
La Jolla Pharmaceutical
GCS-100
chronic kidney disease
Flag link:
FDA Agrees that La Jolla Pharmaceutical Has Sufficient Data for Investigational New Drug Application
FDA Agrees that La Jolla Pharmaceutical Has Sufficient Data for Investigational New Drug Application
San Diego Business Journal, CA
La Jolla Pharmaceutical
LJPC-501
hepatorenal syndrome
Flag link:
4 Small Biotechs With Big Clinical Trials Presenting In 2013
4 Small Biotechs With Big Clinical Trials Presenting In 2013
Seeking Alpha
perifosine
Aeterna Zentaris
Advaxis
GCS-100
La Jolla Pharmaceutical
APPY1
Venaxis
Flag link:
La Jolla Pharmaceutical Company Acquires GCS-100, a First-in-Class Galectin-3 Antagonist
La Jolla Pharmaceutical Company Acquires GCS-100, a First-in-Class Galectin-3 Antagonist
Enhanced Online News
GCS-100
La Jolla Pharmaceutical
Flag link:
La Jolla Pharmaceutical, Adamis Pharmaceuticals to terminate merger agreement
La Jolla Pharmaceutical, Adamis Pharmaceuticals to terminate merger agreement
The Medical News
La Jolla Pharmaceutical
Adamis Pharmaceuticals
Flag link:
La Jolla Pharma to be delisted after merger flop
La Jolla Pharma to be delisted after merger flop
Fierce Biotech
La Jolla Pharmaceutical
Flag link:
La Jolla Pharmaceutical Company Provides Responses to Frequently Asked Questions about Merger Vote
La Jolla Pharmaceutical Company Provides Responses to Frequently Asked Questions about Merger Vote
Yahoo/BusinessWire
La Jolla Pharmaceutical
Adamis Pharmaceuticals
M&A
Flag link:
La Jolla Pharmaceutical Finally Slain by the Wolf as Luck Runs Out
La Jolla Pharmaceutical Finally Slain by the Wolf as Luck Runs Out
BNET Pharma
La Jolla Pharmaceutical
Riquent
lupus
Flag link:
La Jolla Pharma axes plan to dissolve company
La Jolla Pharma axes plan to dissolve company
Yahoo/AP
La Jolla Pharmaceutical
Flag link:
The 2009 Biotech Graveyard
The 2009 Biotech Graveyard
Fierce Biotech
biotech
Alizyme
Akesis
Altus
Argolyn
AtheroGenics
Diobex
Biopure
Dynogen
Epix
La Jolla Pharmaceutical
MicroIslet
Nanogen
Northfield Labs
Neurobiological Technologies
Orchestra Therapeutics
Torrey Pines
Flag link:
La Jolla Pharmaceutical Company Receives Notice of Noncompliance with Nasdaq Stock Market Listing Requirement
La Jolla Pharmaceutical Company Receives Notice of Noncompliance with Nasdaq Stock Market Listing Requirement
Business Wire
La Jolla Pharmaceutical
Flag link:
La Jolla Is Too Much of a Gamble Right Now
La Jolla Is Too Much of a Gamble Right Now
Seeking Alpha
La Jolla Pharmaceutical
Cell Genesys
Flag link:
La Jolla Pharmaceutical Company Announces Going Concern Opinion and Receipt of Nasdaq Staff Deficiency Letter
La Jolla Pharmaceutical Company Announces Going Concern Opinion and Receipt of Nasdaq Staff Deficiency Letter
Yahoo
NASDAQ
La Jolla Pharmaceutical
Flag link:
Q1 2009 Biotech Roundup: The Good, the Bad and the Ugly
Q1 2009 Biotech Roundup: The Good, the Bad and the Ugly
Seeking Alpha
biotech
Acorda Therapeutics
CV Therapeutics
Arena Pharmaceuticals
Genentech
Gilead Sciences
ZymoGenetics
ViroPharma
MAP Pharmaceuticals
Synta
La Jolla Pharmaceutical
Indevus
InterMune
Osiris Therapeutics
Flag link:

Pages